https://orcid.org/0000-0002-3575-780X
References
- Brown JH, Brandl K, Wess J. Muscarinic receptor agonists and antagonists. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & gilman’s: the pharmacological basis of therapeutics. 13th ed. New York (NY): McGraw-Hill Education; 2017.
- Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128–138.e2.
- Liu V, Farshchian M, Potts GA. Management of primary focal hyperhidrosis: an algorithmic approach. J Drugs Dermatol. 2021;20(5):523–528.
- Qbrexza (glycopyrronium tosylate) [package insert]. Menlo Park (CA): Demira, Inc.; 2018.
- Glaser DA, Hebert AA, Nast A, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593–604.
- Lakraj AA, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013;5(4):821–840.
- Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics. 1973;52(3):449–451.
- Al-Holou SN, Lipsky SN, Wasserman BN. Don’t sweat the blown pupil: anisocoria in patients using qbrexza. Ophthalmology. 2020;127(10):1381.
- Pariser DM, Lain EL, Mamelok RD, et al. Limited systemic exposure with topical glycopyrronium tosylate in primary axillary hyperhidrosis. Clin Pharmacokinet. 2021;60(5):665–676.
- Kearney TE. Chapter 223. Physostigmine and neostigmine. In: Olson KR, editor. Poisoning & drug overdose. 6th ed. New York (NY): The McGraw-Hill Companies; 2012.
- Senapathi TGA, Wiryana M, Subagiartha IM, et al. Effectiveness of intramuscular neostigmine to accelerate bladder emptying after spinal anesthesia. Ther Clin Risk Manag. 2018;14:1685–1689.
- Van Kernebeek MW, Ghesquiere M, Vanderbruggen N, et al. Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication. Clin Toxicol (Phila). 2021;59(5):447–448.
- Hughes AR, Moore KK, Mah ND, et al. Letter in response to Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication. Clin Toxicol (Phila). 2021;59(9):855–856.